10-Q · May 12, 2026
Acumen Pharmaceuticals reported a net loss of $20.7 million for Q1 2026, resulting in a diluted EPS of -$0.41, better than analysts' expected -$0.53. Revenue remains undisclosed. The company decreased its operating…
Earnings analysis · 10-Q
ABOS earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Acumen’s Q2 diluted EPS loss of $(0.45) missed the $(0.40) consensus estimate and worsened sequentially from $(0.33), although it improved versus $(0.68) a year earlier. The operating loss narrowed to $32.6 million as…
Read full summary
Acumen’s Q2 diluted EPS loss of $(0.45) missed the $(0.40) consensus estimate and worsened sequentially from $(0.33), although it improved versus $(0.68) a year earlier. The operating loss narrowed to $32.6 million as R&D fell to $27.8 million, but the company remains dependent on $110.2 million of liquidity expected to fund activities only into early 2027. The principal near-term catalysts are ALTITUDE-AD topline data in late 2026 and an EBD IND filing in mid-2027, while the end of emerging-growth-company status on December 31, 2026 and planned insider sales add risk.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.45
What stood out
-
EPS missed estimates; mixed year-over-year trend
Q2 diluted EPS was $(0.45), missing the $(0.40) consensus estimate by $0.05. EPS deteriorated from $(0.33) in Q1 2026 but improved from $(0.68) in Q2 2025.
-
Lower R&D reduced operating loss
The operating loss narrowed to $32.6 million from $41.8 million in the prior-year quarter, as R&D expense declined to $27.8 million from $37.1 million.
-
Pipeline milestones remain on schedule
Management continued to target ALTITUDE-AD topline results in late 2026 and a lead EBD candidate IND filing in mid-2027, providing defined clinical and regulatory milestones.
-
No reported control deficiencies
Disclosure controls were deemed effective as of June 30, 2026, and the company reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Equity plan adds flexibility and safeguards
Stockholders approved an amended equity plan increasing shares available for issuance by 10,000,000, while removing the automatic evergreen increase provision and prohibiting option repricing without stockholder approval.
What to watch
-
Limited runway amid continuing losses
The company remains loss-making, with a Q2 operating loss of $32.6 million. Cash, cash equivalents and marketable securities of $110.2 million were expected to fund current activities only into early 2027, indicating continued financing risk.
-
Clinical and regulatory execution risk
ALTITUDE-AD topline results are expected in late 2026 and the EBD IND filing is targeted for mid-2027. Delays or unfavorable outcomes around these two milestones could materially affect valuation and liquidity.
-
Emerging-growth-company status ends
The company anticipates ceasing to qualify as an emerging growth company on December 31, 2026. It would lose certain exemptions, including the auditor-attestation exemption under Section 404 of Sarbanes-Oxley, potentially increasing compliance costs and disclosure burden.
-
Planned insider sales may pressure stock
New Rule 10b5-1 plans permit senior executives to sell up to 1,011,570 specifically identified shares, excluding additional shares sold for tax obligations: 294,858 by the CEO, 616,591 by the CFO, and 100,121 by the chief regulatory officer.
-
Expanded equity pool creates dilution
The amended equity plan increased the available share pool by 10,000,000 shares, creating potential future dilution despite removal of the evergreen provision.
Management's outlook
No numeric revenue or EPS guidance was provided. Management maintained expectations for ALTITUDE-AD topline results in late 2026 and a lead EBD candidate IND filing in mid-2027; cash, cash equivalents and marketable securities of $110.2 million were expected to support current activities into early 2027.
Earlier filings 4
10-K · March 26, 2026
Acumen is a clinical-stage, pre-revenue biopharma focused on sabirnetug (ACU193), an Aß oligomer-selective monoclonal antibody in Phase 2 (ALTITUDE-AD) with top-line results expected in late 2026. The company is also…
10-Q · November 12, 2025
Acumen (ABOS) reported Q3 2025 net loss per share of $(0.44) and a quarterly net loss of $26,451 thousand, both modestly improved versus Q3 2024. R&D and total operating expenses declined year-over-year, while cash and…
10-K · March 27, 2025
Acumen (ABOS) is a clinical-stage biopharmaceutical company advancing sabirnetug (ACU193), an AßO‑selective monoclonal antibody, through a Phase 2 program (ALTITUDE‑AD). The company completed enrollment in ALTITUDE‑AD…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.